A supplemental New Drug Application (sNDA) for Pfizer’s Talzenna (talazoparib) in combination with Xtandi (enzalutamide) has been accepted for Priority Review by the US FDA. The application is to ...

Takeda has announced new data from the two pivotal phase 3 studies of zasocitinib (TAK-279) in adults with moderate-to-severe ...

Chapple has held senior leadership roles at DontBePatient Intelligence, Alira Health, Innovative Trials, Cognizant and ICON ...

Almirall’s submission to extend its Marketing Authorisation Application (MAA) for Ebglyss (lebrikizumab) to treat moderate-to ...

Independent network The Bloc has appointed Jon Chapman as European Executive Creative Director. Chapman previously held ...

How do we translate individual experiences into support that helps others and create support that feels personal but remains ...

Camena Bioscience, a pioneer in enzymatic DNA synthesis producing complex, high-fidelity gene constructs for AI-driven ...

Commercial pharma launches depend on confident, evidence-led decisions. Yet many launch teams are still working with ...

Following ASCO® 2026, Inizio's experts have shared their perspectives across three thought leadership articles, each ...

Independent healthcare communications consultancy POP Health has appointed Stephanie O’Hagan as Senior Director. O’Hagan has ...

Veradermics has announced positive topline results from its open-label phase 2 clinical trial (Study ‘207’) evaluating ...

New op-ed published by leaders from the Women’s Alzheimer’s Movement at Cleveland Clinic, Alzheimer’s Research UK and the Alzheimer’s Association ...